Transcept Pharmaceuticals, Inc. (TSPT) Reports Q1 EPS Loss of $0.14, Tops Consensus by $0.13
Get Alerts TSPT Hot Sheet
Join SI Premium – FREE
Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) reported Q1 EPS of ($0.14), $0.13 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share